drugset / Trial / NCT05220800

Effects of Intravenous Administered Iron in Non-anemic Iron Deficient Patients With Colorectal Cancer

NCT05220800 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This double-blinded clinical randomized trial with a 1:1 recruitment ratio between placebo and the active group will aim to investigate the effects of intravenously administered iron in non-anemic iron deficient patients on physical capacity, immunological cells and their function prior to surgery. A total of 134 patients with colorectalcancer will be included in the study. Study outline: After initial inclusion the patient will undergo baseline testing with cardiopulmonary exercise test (CPET), then followed by an infusion of a weight dependent dosage of iron(III)isomaltoside or placebo. Then at the closest possible time to the surgery the patient will have drawn bloodwork and be re-tested by (CPET). The patient will be followed after surgery with evaluation of several outcomes including quality of recovery and complications. Further, the effects of the intervention on the patients immune function will be evaluated by two different methods: 1) by changes in neutrophil-to-lymphocyte ratio between baseline and preoperative bloodwork and 2) by evaluation mRNA expression in the tumor specimen by the Nanostring pancancer immune panel

Timeline

Start
2022-03-01
Primary completion
2024-03-01
Completion
2029-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Iron(III)isomaltoside Unknown 500 mg Intravenous
Subject Iron(III)isomaltoside Unknown 600 mg Intravenous
Subject Iron(III)isomaltoside Unknown 700 mg Intravenous
Subject Iron(III)isomaltoside Unknown 800 mg Intravenous
Subject Iron(III)isomaltoside Unknown 900 mg Intravenous
Subject Iron(III)isomaltoside Unknown 1000 mg Intravenous